Trial Profile

Phase I clinical trial of cereblon E3 ligase modulator (CELMoD) .

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 03 Dec 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cereblon-E3-ligase-modulator-Bristol-Myers-Squibb/Evotec-SE (Primary)
Indications Unspecified
Focus Adverse reactions

Most Recent Events

03 Dec 2025 New trial record
12 Nov 2025 According to an Evotec SE media release, the company announced that it has received a US$ 5 m milestone payment from Bristol Myers Squibb, following the acceptance of an Investigational New Drug application by the U.S. Food and Drug Administration in their strategic protein degradation partnership. The company plans to initiate Phase 1 clinical trial in 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com